

March 28, 2023

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

**[Updated] Non-Consolidated Financial Results (Japanese GAAP)
for the Fiscal Year Ended December 31, 2022**

Chiome Bioscience makes some corrections to “Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2022” released on February 14, 2023.

The corrections are underlined as shown on the following pages.

Content of the Revision

➤ Summary Information Page2, Notes: (2) Number of Shares Issued (Common Stock)

[Before Updated]

1) Number of shares issued as of the end of the period (including treasury stock)	As of Dec. 31, 2022	48,423,500 shares	As of Dec. 31, 2021	40,781,500 shares
2) Number of treasury stock as of the end of the period	As of Dec. 31, 2022	147 shares	As of Dec. 31, 2021	146 shares
3) Average number of shares for the period (cumulative total for the period)	Fiscal year ended Dec. 31, 2022	<u>43,984,734</u> shares	Fiscal year ended Dec. 31, 2021	40,277,819 shares

[After Updated]

1) Number of shares issued as of the end of the period (including treasury stock)	As of Dec. 31, 2022	48,423,500 shares	As of Dec. 31, 2021	40,781,500 shares
2) Number of treasury stock as of the end of the period	As of Dec. 31, 2022	147 shares	As of Dec. 31, 2021	146 shares
3) Average number of shares for the period (cumulative total for the period)	Fiscal year ended Dec. 31, 2022	<u>43,983,830</u> shares	Fiscal year ended Dec. 31, 2021	40,277,819 shares

[Before Updated]

	(Yen)	
	Fiscal Year Ended Dec. 31, 2021 (Jan. 1, 2021 to Dec. 31, 2021)	Fiscal Year Ended Dec. 31, 2022 (Jan. 1, 2022 to Dec. 31, 2022)
Net assets per share	45.55	36.70
Net loss per share	(36.74)	(28.26)

Notes:

- Details regarding diluted net income per share are not provided despite the existence of shares with the potential to have a dilutive effect. This is because of the net loss for the period.
- The basis for calculations are presented as follows:
 - Net assets per share

(Thousand yen unless otherwise stated)

	As of Dec. 31, 2021	As of Dec. 31, 2022
Total net assets	1,893,049	1,790,746
Amount deducted from total net assets	35,394	13,554
(New subscription rights to shares)	(35,394)	(13,554)
Net assets allocated to capital stock	1,857,654	1,777,192
Number of shares of capital stock used to calculate net assets per share (shares)	40,781,354	48,423,353

- Net loss per share

(Thousand yen unless otherwise stated)

	Fiscal Year Ended Dec. 31, 2021 (Jan. 1, 2021 to Dec. 31, 2021)	Fiscal Year Ended Dec. 31, 2022 (Jan. 1, 2022 to Dec. 31, 2022)
Net loss	(1,479,895)	(1,242,871)
Amount not attributable to shareholders of capital stock	—	—
Net loss allocated to capital stock	(1,479,895)	(1,242,871)
Average number of shares for the period (shares)	40,277,819	<u>43,984,734</u>
Details of dilutive shares not included in calculations relating to net income per diluted share because there was no dilutive effect	New subscription rights to shares: 4 types Number of subscription rights to shares: 78,900	New subscription rights to shares: 2 types Number of subscription rights to shares: 3,170

[After Updated]

(Yen)

	Fiscal Year Ended Dec. 31, 2021 (Jan. 1, 2021 to Dec. 31, 2021)	Fiscal Year Ended Dec. 31, 2022 (Jan. 1, 2022 to Dec. 31, 2022)
Net assets per share	45.55	36.70
Net loss per share	(36.74)	(28.26)

Notes:

- Details regarding diluted net income per share are not provided despite the existence of shares with the potential to have a dilutive effect. This is because of the net loss for the period.
- The basis for calculations are presented as follows:
 - Net assets per share

(Thousand yen unless otherwise stated)

	As of Dec. 31, 2021	As of Dec. 31, 2022
Total net assets	1,893,049	1,790,746
Amount deducted from total net assets	35,394	13,554
(New subscription rights to shares)	(35,394)	(13,554)
Net assets allocated to capital stock	1,857,654	1,777,192
Number of shares of capital stock used to calculate net assets per share (shares)	40,781,354	48,423,353

- Net loss per share

(Thousand yen unless otherwise stated)

	Fiscal Year Ended Dec. 31, 2021 (Jan. 1, 2021 to Dec. 31, 2021)	Fiscal Year Ended Dec. 31, 2022 (Jan. 1, 2022 to Dec. 31, 2022)
Net loss	(1,479,895)	(1,242,871)
Amount not attributable to shareholders of capital stock	—	—
Net loss allocated to capital stock	(1,479,895)	(1,242,871)
Average number of shares for the period (shares)	40,277,819	<u>43,983,830</u>
Details of dilutive shares not included in calculations relating to net income per diluted share because there was no dilutive effect	New subscription rights to shares: 4 types Number of subscription rights to shares: 78,900	New subscription rights to shares: 2 types Number of subscription rights to shares: 3,170

【Inquiries】

Chiome Bioscience Inc. Investor Relations

E-mail : ir@chiome.co.jp